RecruitingNot Applicable

Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study

China7,000 participantsStarted 2023-07-18

Plain-language summary

The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD). The main question\[s\] it aims to answer are: \[question 1\] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? \[question 2\] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of diabetes mellitus: (1) taking glucose-lowering drugs; (2) HbA1c ≥ 6.5% (48 mmol/mol); (3) fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL); (4) 2-hour plasma glucose (2hPG) ≥ 11.1 mmol/L (200 mg/dL).
✓. Overweight or obesity: defined as BMI≥25 kg/m2 in Caucasians or BMI≥23 kg/m2 in Asians
✓. If presence of at least two metabolic risk abnormalities:

What they're measuring

Controlled attenuation parameter

Timeframe: at baseline

Trial details

NCT IDNCT05974904

SponsorChongqing Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-28

Contact for this trial

Tingqiu Wang, Bachelor

+8617815370539 w857683014@163.com

View on ClinicalTrials.gov More Metabolic Dysfunction-associated Fatty Liver Disease trials